Ion Channel News and Research

RSS

Zalicus commences Z160 Phase 1 clinical trial for pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160 (formerly NMED-160), a novel oral N-type calcium channel blocker.

5 Dec 2011

Scientists create genetically-altered neurons that light up as they fire

In a scientific first that potentially could shed new light on how signals travel in the brain, how learning alters neural pathways, and might lead to speedier drug development, scientists at Harvard have created genetically-altered neurons that light up as they fire.

30 Nov 2011

ABCC9 gene also influences duration of sleep in humans

A collaborative European study led by LMU researchers has shown that ABCC9, a known genetic factor in heart disease and diabetes, also influences the duration of sleep in humans.

24 Nov 2011

Study reveals specific functional deficit in inner ear mechanotransduction channels

National Institutes of Health-funded researchers have identified two proteins that may be the key components of the long-sought after mechanotransduction channel in the inner ear-the place where the mechanical stimulation of sound waves is transformed into electrical signals that the brain recognizes as sound.

22 Nov 2011

Gene-therapy trial to restore hearing in deaf mice

Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.

22 Nov 2011

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine.

21 Nov 2011

Researchers describe how brain handles spatial resolution

Everybody knows how to zoom in and out on an online map, to get the level of resolution you need to get you where you want to go. Now researchers have discovered a key mechanism that can act like a zoom button in the brain, by controlling the resolution of the brain's internal maps.

18 Nov 2011

Research shows how the bite of a small Texas snake causes extreme pain

Examining venom from a variety of poisonous snakes, a group of researchers at the University of California, San Francisco has discovered why the bite of one small black, yellow and red serpent called the Texas coral snake can be so painful.

17 Nov 2011

New computer chip models how neurons communicate with each other at synapses

For decades, scientists have dreamed of building computer systems that could replicate the human brain's talent for learning new tasks. MIT researchers have now taken a major step toward that goal by designing a computer chip that mimics how the brain's neurons adapt in response to new information. This phenomenon, known as plasticity, is believed to underlie many brain functions, including learning and memory.

16 Nov 2011

Researchers identify how to design drugs to target specific brain areas

The future of drug design lies in developing therapies that can target specific cellular processes without causing adverse reactions in other areas of the nervous system. Scientists at the Universities of Bristol and Li-ge in Belgium have discovered how to design drugs to target specific areas of the brain.

11 Nov 2011

Zalicus third quarter revenue increases to $2.4 million

Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.

2 Nov 2011

Pfizer acquires Icagen

Pfizer Inc. announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.

29 Oct 2011

Researchers uncover molecular pathway critical to cardiac arrhythmia

University of Maryland School of Medicine researchers have uncovered a previously unknown molecular pathway that is critical to understanding cardiac arrhythmia and other heart muscle problems.

27 Oct 2011

New insights into nephrotic syndrome and high blood pressure

Scientists have now begun to understand kidney damage on a cellular level and how the activity of certain molecules in damaged kidneys contributes to salt and water retention in nephrotic syndrome.

23 Sep 2011

U-M Professor to review data from three prominent studies on heart failure

Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists.

20 Sep 2011

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator.

20 Sep 2011

UNC researchers develop technique that can observe cellular intricacies of CF

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.

20 Sep 2011

High dietary salt intake and obesity together trigger abnormal activation of cellular protein

Dietary salt intake and obesity are two important risk factors in the development of high blood pressure. Each packs its own punch, but when combined, they deliver more damage to the heart and kidneys than the sum of their individual contributions.

19 Sep 2011

Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing.

16 Sep 2011

UB transgenic mouse model of Timothy Syndrome improves understanding of autism

The first transgenic mouse model of a rare and severe type of autism called Timothy Syndrome is improving the scientific understanding of autism spectrum disorder in general and may help researchers design more targeted interventions and treatments.

12 Sep 2011